Partnering With Patients in the Treatment of Psoriatic Arthritis
Biosimilars: Addressing Uncertainties With a New Drug Class
Expert Answers to Frequently Asked Questions About Biosimilars
Targeting IL-17 in Psoriatic Arthritis: Key Data From the 2016 ACR Meeting
Rheumatology in Practice: Assessing Disease Activity in Psoriatic Arthritis
Conference CoverageEducationClinical ThoughtDecision SupportCCO Live EventsSlidesets
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.